Epithalamin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-27 and is reviewed periodically as new material appears.
The peptide emerged from research carried out in Saint Petersburg from the late 1980s onward, where investigators searched for shorter active fragments of a pineal preparation known as epithalamin. The name epitalon was chosen to reflect that parent extract. Early reports described effects on neuroendocrine markers and on the lifespan of laboratory animals. Much of that work appeared in Russian-language journals, with English translations following later, which affects how readily the original protocols can be assessed by outside groups.
Published studies on epitalon are dominated by a small number of research groups, and independent replication in other laboratories remains limited. Proposed mechanisms include activation of telomerase and modulation of melatonin rhythms, but the evidence for either rests mainly on cell cultures and animal models. Whether the peptide produces comparable effects in humans is an open question, and the absence of large controlled trials means the literature is best read as exploratory rather than settled.
Epitalon is a synthetic four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9, and its calculated molar mass is approximately 390.35 grams per mole. The compound is a short fragment related to a peptide fraction isolated from bovine pineal gland extracts, and it is normally supplied as a lyophilised powder intended for laboratory research. It is not a registered pharmaceutical product in most countries.
Epitalon is a synthetic tetrapeptide whose sequence is alanine-glutamate-aspartate-glycine, written in single-letter code as AEDG. The four residues are joined by three peptide bonds, giving a linear backbone with no branching and no disulfide bridges. Its calculated molecular mass for the free form is approximately 390.3 daltons, a figure that rises when the compound is supplied as an acetate or trifluoroacetate salt. Because the chain is short, the molecule is defined entirely by its residue order rather than by any folded three-dimensional structure.
The compound is described in the literature as a derivative of epithalamin, a preparation obtained from bovine pineal tissue. Work on this peptide family was carried out mainly by a research group in Saint Petersburg beginning in the 1980s, and the substance was later registered for clinical use in Russia under the name Epitalon. Outside that region it is generally treated as a research chemical rather than an approved medicine. Statements about its biological activity rest on a relatively small number of studies, and independent replication remains limited.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C14H22N4O9 | Derived from the four-residue sequence |
| Molar mass | About 390.35 g/mol | Free peptide, counter-ion not included |
| Appearance | White to off-white powder | Lyophilised solid from aqueous solution |
| Water solubility | Freely soluble | Short, polar peptide chain |
| Common synonyms | AEDG; epithalone | Catalogues use the names interchangeably |
Epitalon is a synthetic tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. Its design traces to epithalamin, a peptide fraction prepared from bovine pineal gland extracts that researchers in Saint Petersburg began investigating in the 1970s. The compound has a molecular formula of C14H22N4O9 and a nominal molecular mass near 390 daltons. It holds no approved drug status in the United States or the European Union, and material sold under this name is generally offered as a research chemical rather than a finished pharmaceutical product.
Proposed mechanisms centre on cell-culture observations rather than a defined receptor interaction. Several reports describe increased expression of the telomerase catalytic subunit after exposure of cultured human cells, and the authors attributed the effect to short peptide fragments entering the nucleus and influencing gene transcription. No receptor for the tetrapeptide has been identified, and the free peptide is expected to be degraded rapidly by plasma peptidases. Whether any measurable fraction reaches intact tissues after administration remains an unresolved question rather than an established finding.
The published literature is dominated by a small number of research groups, much of it in Russian-language journals, and independent replication outside those groups is limited. Studies are typically small, use cultured cells or rodent models, and report endpoints that differ between papers, which makes comparison difficult. Large randomised human trials have not appeared in the indexed literature. Questions about absorption, distribution and clearance are therefore still treated as open in reviews that mention the compound.
The four residues give epitalon a molecular formula of C14H22N4O9 and a molecular weight near 390.35 daltons. The presence of two acidic residues, glutamate and aspartate, makes the free peptide strongly acidic, while the alanine and glycine ends provide neutral, nonpolar character. This combination produces a molecule with substantial water solubility. Because there are no cysteine, methionine, or tryptophan residues, the peptide lacks the most common oxidation-sensitive side chains, which simplifies handling compared with many longer peptides.
The proposed relationship between epitalon and pineal function is a central part of its background. Khavinson's group reported that short peptides corresponding to regions of larger pineal proteins could influence gene expression in cells. Epitalon was framed as a synthetic analogue of an active fragment rather than a direct isolation product. Whether the tetrapeptide reproduces the effects of the parent extract is an open question, because comparative studies are limited and the parent extract itself is not a single defined substance.
Epitalon is a synthetic linear tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and the calculated mass is approximately 390.35 g/mol. The compound is made by solid-phase peptide synthesis rather than extracted from tissue, although early work described it as a short fragment of a peptide fraction obtained from bovine pineal extract. In the research literature the spelling epitalon and the variant epithalone both appear, while AEDG is the standard code used in peptide nomenclature.
Several names circulate for the same molecule, including epitalon, epithalone, epithalamin tetrapeptide, and the sequence code AEDG. A CAS registry number, 307297-39-8, is commonly cited for it, though catalogue entries should be checked against supplier documentation because mislabelled records occur. In its usual form the peptide carries free amino and carboxyl termini and is neither glycosylated nor lipidated. Researchers distinguish the defined tetrapeptide from epithalamin itself, a crude pineal preparation containing many peptides that is not chemically characterised.
Material supplied for laboratory use is normally a lyophilised white to off-white powder that dissolves readily in water and in isotonic saline. Lyophilised cakes are hygroscopic and should be equilibrated to room temperature before opening to limit condensation on the solid. Solutions are typically prepared at milligram-per-millilitre concentrations and divided into single-use aliquots, because repeated freeze–thaw cycles degrade short peptides. Aqueous solutions are far less stable than the dry powder, and identity is usually verified by mass spectrometry alongside purity estimation from reversed-phase high-performance liquid chromatography.
Epitalon is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. It was designed at the St. Petersburg Institute of Bioregulation and Gerontology as a short, chemically defined analogue of epithalamin, a fraction obtained from bovine pineal tissue. Small peptide bioregulators of this type formed a long-running line of work there from the 1980s onward. Because the molecule is produced by solid-phase synthesis rather than extraction, its composition is exact and its purity can be measured directly.
The most frequently cited proposed action is induction of telomerase, the enzyme that adds repeat sequences to chromosome ends. Cell-culture work from the originating group reported higher telomerase reverse transcriptase expression and measurable telomere elongation in human somatic cells after exposure. How a four-residue peptide would reach nuclear gene regulation is not established, and no cell-surface receptor or uptake route has been identified. Additional reports describe changes in melatonin secretion, antioxidant enzyme activity and lipid peroxidation in aged animals, but these findings remain mechanistically unconnected to the telomerase observation.
Published evidence comes mainly from Russian-language journals and from a single research group, with small sample sizes and limited independent replication. A few laboratories outside that group have examined related peptides and reported weaker or absent telomerase effects, so the central claim is best described as contested rather than settled. Rodent studies report modest changes in some ageing markers and in survival, but designs vary and control conditions are often sparse. No large randomised trial in humans has been published, and long-term safety data in healthy populations are correspondingly thin.
== Further reading == Hammond, Julia (July 3, 2019). "The truth about the US' most iconic food". BBC Travel. Loftus, Jamie (2023). Raw Dog: The Naked Truth About Hot Dogs. New York: Tor Publishing Group. ISBN 978-1-250-84774-4. OCLC 1372498488.
== Classes and roles == Bacterial glutathione transferases are widely distributed in aerobic bacteria and are classified into several classes. These classes are organized according to the protein sequence and structure. In bacteria, the theta class GSTs includes all of the currently known bacterial glutathione transferases. Between classes, these proteins have less than 25% sequence identity, while members of the same class match about 40% amino acid sequence identity. In comparison to eukaryotes, studies have shown that most of the residues that are highly conserved in theta and other bacterial class GSTs are not retained in those of the alpha, mu, and pi classes of eukaryotic GSTs. The considerable amount of protein sequence variation has led to the general belief that GSTs carry out a very wide variety of glutathione-dependent conjugation functions. No other currently known proteins have the same overall topology as GST enzymes. Bacterial glutathione transferases are not detected in anaerobic bacteria or archaea. These antioxidant enzymes are a part of the glutathione biosynthetic pathway, which is present in cyanobacteria, proteobacteria, and certain Gram-negative bacteria. Bacterial GSTs are involved in a variety of distinct processes such as biotransformation of toxic compounds, protection against several stresses, and antibacterial drug resistance. GSTs also have important roles in metabolism, such as signaling-ligand biosynthesis, tyrosine depredation, peroxide breakdown, and dehydroascorbate reduction.
==== MeSH E05.393.285 – cytogenetic analysis ==== MeSH E05.393.285.130 – chromosome banding MeSH E05.393.285.350 – in situ hybridization, fluorescence MeSH E05.393.285.350.125 – chromosome painting MeSH E05.393.285.350.125.800 – spectral karyotyping MeSH E05.393.285.475 – karyotyping MeSH E05.393.285.475.800 – spectral karyotyping MeSH E05.393.285.830 – sex determination (analysis)
Sources: en.wikipedia.org
Protein tags are peptide sequences genetically grafted onto a recombinant protein. Tags are attached to proteins for various purposes. They can be added to either end of the target protein, so they are either C-terminus or N-terminus specific or are both C-terminus and N-terminus specific. Some tags are also inserted at sites within the protein of interest; they are known as internal tags. Affinity tags are appended to proteins so that they can be purified from their crude biological source using an affinity technique. Affinity tags include chitin binding protein (CBP), maltose binding protein (MBP), Strep-tag and glutathione-S-transferase (GST). The poly(His) tag is a widely used protein tag, which binds to matrices bearing immobilized metal ions. Solubilization tags are used, especially for recombinant proteins expressed in species such as E. coli, to assist in the proper folding in proteins and keep them from aggregating in inclusion bodies. These tags include thioredoxin (TRX) and poly(NANP). Some affinity tags have a dual role as a solubilization agent, such as MBP and GST. Chromatography tags are used to alter chromatographic properties of the protein to afford different resolution across a particular separation technique. Often, these consist of polyanionic amino acids, such as FLAG-tag or polyglutamate tag. Epitope tags are short peptide sequences which are chosen because high-affinity antibodies can be reliably produced in many different species. These are usually derived from viral genes, which explain their high immunoreactivity.
He went on to lose all three semifinals to the eventual champion of all three events, Jannik Sinner, failing to win a set in any of the three matches and extending his ongoing losing streak to eight consecutive losses against the Italian. Zverev then failed to defend the title in Munich, being defeated by Flavio Cobolli in the semifinals. In Madrid, Zverev advanced to his fourth final in the Magic Box, a first Masters 1000 final of the season for a chance at a third Madrid Open title. He went on to lose to Sinner again in straight sets. The following week, he was upset by home favourite Luciano Darderi at the round of 16 of the Italian Open, ending his run of five successive Masters 1000 semifinals dating back to the Paris Masters. At the French Open, Zverev won his maiden major title. He entered the tournament as the second seed, after two-time defending champion Carlos Alcaraz withdrew due to an ongoing wrist injury. Following Jannik Sinner's abrupt loss to Juan Manuel Cerundolo and three-time French Open champion Novak Djokovic's loss to Joāo Fonseca, Zverev was widely labelled the tournament favourite, a label he distanced himself from as the tournament progressed. By reaching his sixth consecutive quarterfinal appearance in Paris, Zverev joined Roger Federer, Rafael Nadal, and Djokovic as the only men's singles players to achieve this feat. He then advanced to his second French Open final and fourth major final following wins against Rafael Jódar in the quarterfinals and Jakub Menšík in the semifinal.
In November 2024, an investigation by The Washington Post further corroborated these investigations, with witnesses, victims, and an Israeli soldier stating civilians were being used as human shields to prevent harm to Israeli soldiers. An investigation by the DCIP detailed that the Israeli army is "systematically" detaining and torturing children. Israel used several children as human shields in the Al-Tuffah area of Gaza City on 27 December 2023. On that occasion, 50 Palestinians were detained, including children. Two brothers, aged 12 and 13, told investigators that soldiers forced them to strip off, tied their hands and forced them to walk in front of Israeli tanks along with other Palestinians. The younger brother also reported being slapped, kicked and beaten. In November 2024, Defence for Children International reported on three separate incidents, during 15–20 October 2024, of families with young children being used as human shields to protect the Israel Defense Forces in attacks at the Jabalia refugee camp and Indonesia Hospital.
Sources: en.wikipedia.org
It is a synthetic tetrapeptide built from alanine, glutamate, aspartate and glycine. The four residues are joined by standard peptide bonds, giving a linear chain rather than a branched structure.
The name derives from epithalamin, a pineal gland extract studied in the former Soviet Union. Researchers proposed that short fragments of that extract carried the biological activity of interest.
No major regulatory agency has approved it as a medicine. It is handled as a research chemical, and products sold under this name are not standardised drugs with defined clinical labelling.
The peptide contains four residues in the order alanine, glutamate, aspartate and glycine, abbreviated AEDG. The chain is linear and held together by three peptide bonds. Its calculated mass for the uncharged free form is about 390.3 daltons.